Cover Image

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n =...

Full description

Saved in:
Bibliographic Details
Main Authors: Johansen, Julia S. (Author) , Calatayud, Dan (Author) , Albieri, Vanna (Author) , Schultz, Nicolai A. (Author) , Dehlendorff, Christian (Author) , Werner, Jens (Author) , Jensen, Benny V. (Author) , Pfeiffer, Per (Author) , Bojesen, Stig E. (Author) , Giese, Nathalia (Author) , Nielsen, Kaspar R. (Author) , Nielsen, Svend E. (Author) , Yilmaz, Mette (Author) , Holländer, Niels H. (Author) , Andersen, Klaus K. (Author)
Format: Article (Journal)
Language:English
Published: [2016]
In: International journal of cancer
Year: 2016, Volume: 139, Issue: 10, Pages: 2312-2324
ISSN:1097-0215
DOI:10.1002/ijc.30291
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.30291
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30291
Get full text
Author Notes:Julia S. Johansen, Dan Calatayud, Vanna Albieri, Nicolai A. Schultz, Christian Dehlendorff, Jens Werner, Benny V. Jensen, Per Pfeiffer, Stig E. Bojesen, Nathalia Giese, Kaspar R. Nielsen, Svend E. Nielsen, Mette Yilmaz, Niels H. Holländer and Klaus K. Andersen
Description
Summary:Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n = 111). Controls included 59 patients with chronic pancreatitis (CP) and 248 healthy subjects (HS). MiRNAs were analyzed in pretreatment serum samples from 3 cohorts: discovery cohort (754 human miRNAs, TaqMan® Human MicroRNA assay, Applied Biosystem; PC n = 133, controls n = 72); training cohort (34 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 198, controls n = 184); validation cohort (13 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 86, controls n = 51). We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, −18a, −20a, −24, −25, −27a, −29c, −30a.5p, −191, −323.3p, −345 and −483.5p). Diagnostic accuracy of detecting PC in the training cohort was AUC (Index I 0.85; II 0.87; III 0.85; IV 0.95; CA 19-9 0.93); specificity (I 0.71; II 0.76; III 0.66; IV 0.90 (fixed sensitivity at 0.85); CA 19-9 0.93). Combining serum CA 19-9 and Index II best discriminated Stages I and II PC from HS [AUC 0.93 (0.90-0.96), sensitivity 0.77 (0.69-0.84), specificity 0.94 (0.90-0.96) and accuracy 0.88 (0.84-0.91)]. In conclusion, we identified four diagnostic panels based on 5 or 12 miRNAs in serum that could distinguish patients with PC from HS and CP.
Item Description:Gesehen am 06.05.2020
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.30291

Similar Items